CL2022003372A1 - Una composición que comprende hp-hmg para su uso en el tratamiento de la infertilidad - Google Patents

Una composición que comprende hp-hmg para su uso en el tratamiento de la infertilidad

Info

Publication number
CL2022003372A1
CL2022003372A1 CL2022003372A CL2022003372A CL2022003372A1 CL 2022003372 A1 CL2022003372 A1 CL 2022003372A1 CL 2022003372 A CL2022003372 A CL 2022003372A CL 2022003372 A CL2022003372 A CL 2022003372A CL 2022003372 A1 CL2022003372 A1 CL 2022003372A1
Authority
CL
Chile
Prior art keywords
infertility
hmg
treatment
composition
stimulation
Prior art date
Application number
CL2022003372A
Other languages
English (en)
Inventor
Heiser Patrick
Foster Eric
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20182800.1A external-priority patent/EP3932419A1/en
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2022003372A1 publication Critical patent/CL2022003372A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una tecnología de reproducción asistida mejorada para mujeres que se prevé que tienen una respuesta ovárica alta a la estimulación ovárica controlada que comprende el direccionamiento a un nivel de hCG sérica umbral el día final de la estimulación.
CL2022003372A 2020-05-29 2022-11-29 Una composición que comprende hp-hmg para su uso en el tratamiento de la infertilidad CL2022003372A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032430P 2020-05-29 2020-05-29
EP20182800.1A EP3932419A1 (en) 2020-06-29 2020-06-29 Methods of treating infertility

Publications (1)

Publication Number Publication Date
CL2022003372A1 true CL2022003372A1 (es) 2023-08-04

Family

ID=76059912

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003372A CL2022003372A1 (es) 2020-05-29 2022-11-29 Una composición que comprende hp-hmg para su uso en el tratamiento de la infertilidad

Country Status (14)

Country Link
US (1) US20230210955A1 (es)
EP (1) EP4157323A1 (es)
JP (1) JP2023527221A (es)
KR (1) KR20230018428A (es)
CN (1) CN115803046A (es)
AU (1) AU2021281055A1 (es)
BR (1) BR112022023176A2 (es)
CA (1) CA3182102A1 (es)
CL (1) CL2022003372A1 (es)
CO (1) CO2022017203A2 (es)
IL (1) IL298550A (es)
MX (1) MX2022015031A (es)
TW (1) TW202210096A (es)
WO (1) WO2021239961A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186331A1 (en) * 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3261661T3 (pl) * 2015-02-26 2024-03-25 Ferring B.V. Menotropina do leczenia niepłodności

Also Published As

Publication number Publication date
CO2022017203A2 (es) 2022-12-09
TW202210096A (zh) 2022-03-16
EP4157323A1 (en) 2023-04-05
JP2023527221A (ja) 2023-06-27
BR112022023176A2 (pt) 2023-01-10
KR20230018428A (ko) 2023-02-07
WO2021239961A1 (en) 2021-12-02
MX2022015031A (es) 2023-01-04
US20230210955A1 (en) 2023-07-06
IL298550A (en) 2023-01-01
CN115803046A (zh) 2023-03-14
CA3182102A1 (en) 2021-12-02
AU2021281055A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2020001575A1 (es) Anticuerpos anti-trem2 y métodos relacionados.
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
BR112018016226A2 (pt) anticorpo antilipoarabinomanana (anti-lam) monoclonal humano, anticorpos anti-lam monoclonal humano, anticorpo anti-pim6/lam monoclonal humano, kit para detectar pelo menos um epítopo de lam, método para diagnosticar uma infecção de tuberculose ativa em um indivíduo, e método para tratar uma infecção de tuberculose em um indivíduo
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112015021392A2 (pt) uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
CL2022003372A1 (es) Una composición que comprende hp-hmg para su uso en el tratamiento de la infertilidad
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
CL2017002729A1 (es) Proteína de unión a rgma y su uso
CL2019003402A1 (es) Composiciones sólidas para administración oral.
AR069479A1 (es) Composiciones y metodos para inhibir la activacion de la proteina quinasa dependiente de arnds e inhibicion de crecimiento tumoral
CO2022003582A2 (es) Métodos para el tratamiento de la oftalmopatía tiroidea
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
CO2021007006A2 (es) Moduladores de la expresión de irf5
UY38721A (es) INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
CL2022001368A1 (es) Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
CO2022000266A2 (es) Inhibidores de enzimas